Hematology drug developer Geron Q3 narrows net loss narrows, driven by RYTELO sales

Geron

05/11/2025 12:08

Overview

Geron Q3 2025 revenue rises to $47.2 mln, driven by RYTELO sales

Net loss for Q3 2025 narrows to $18.4 mln from $26.4 mln in 2024

Operating income for Q3 2025 beats analyst expectations

Outlook

Company expects 2025 operating expenses between $250 mln and $260 mln

Company anticipates IMpactMF interim analysis in H2 2026

Geron believes existing resources and RYTELO sales will fund future operations

Result Drivers

RYTELO SALES - Achieved $47.2 mln in net product revenue for Q3 2025, despite a 3% decline in demand

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Product Revenue
$47.16 mln
Q3 EPS
-$0.03
Q3 Net Income
-$18.42 mln
Q3 Operating Income
Beat
-$13.88 mln
-$17.30 mln (7 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

Wall Street's median 12-month price target for Geron Corp is $4.00, about 71.3% above its November 4 closing price of $1.15

Press Release: ID:nBw2h2mvSa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)